A platinum nanourchin-based multi-enzymatic platform to disrupt mitochondrial function assisted by modulating the intracellular H 2 O 2 homeostasis.

Jiansen Huang,Yongcan Li,Lei Zhang,Jie Wang,Zhigang Xu,Yuejun Kang,Peng Xue
DOI: https://doi.org/10.1016/j.biomaterials.2022.121572
IF: 14
2022-01-01
Biomaterials
Abstract:Endogenous HO sacrifices for diversified therapeutic reactions against tumor. However, the treatment outcome is not always satisfactory owing to the unsustainable HO supply from tumor microenvironment (TME). Herein, a platinum (Pt) nanourchin-based multi-enzymatic platform (referred to PGMA) is established by surface conjugation of glucose oxidase (GOx) capped with manganese carbonyl (MnCO) and loading 3-amino-1,2,4-triazole (3-AT). The mild acidic and HO-rich TME can render the degradation of MnCO, followed by triggering the release of CO gas, 3-AT and Mn. The resultant GOx exposure initiates intratumoral glucose depletion, which is promoted by the O replenishment through Pt-catalyzed decomposition of HO. Meanwhile, intracellular reactive oxygen species (ROS) level is elevated through Mn couple-mediated Fenton-like reaction. Hence, CO release-initiated gas therapy, glucose exhaustion-induced tumor starvation and ROS-triggered chemodynamic therapy are committed to realizing a combinatorial disruption effect on mitochondrial function. Importantly, the released 3-AT can inhibit the activity of endogenous catalase, which effectively elevates the intracellular HO level to compensate its consumption and provides incremental reactant for cascade utilizations. Taken together, this study aims to emphasize the importance of intracellular HO balance during HO-depleted therapeutic process, and affords a prime paradigm of applying this strategy for tumor treatment via mitochondrial dysfunction.
What problem does this paper attempt to address?